Table 2. Cohorts of dromedary camels by MERS-CoV seroprevalence and vaccine candidate used Dubai, United Arab Emirates*.
| Category | Type | Vaccine candidate |
Total | |
|---|---|---|---|---|
| MVA | MVA-MERS-S | |||
| MERS-CoV infection | Naive | 1 | 3 | 4 |
| Seropositive | 3 | 5 | 8 | |
| Total | 4 | 8 | 12 | |
*MERS-CoV, Middle East respiratory syndrome coronavirus; MVA, modified vaccinia virus Ankara; MVA-MERS-S, modified vaccinia virus Ankara expressing full-length MERS-CoV spike protein as antigen.